Source:http://linkedlifedata.com/resource/pubmed/id/10859533
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3-4
|
pubmed:dateCreated |
2000-8-24
|
pubmed:abstractText |
Retinoids and glucocorticoids are known to have a potential to modulate the expression of transforming growth factor-beta (TGF-beta). We investigated the effect of oral isotretinoin (13-cis-retinoic acid) on the expression of two distinct isoforms of TGF-beta, TGF-beta1 and TGF-beta2, in suction blister fluid and serum in acne patients. We also investigated the effect of topical glucocorticoid (betamethasone-17-valerate) and age on suction blister fluid TGF-beta1 in healthy volunteers. Six weeks of isotretinoin treatment caused a statistically significant 19% increase in suction blister fluid TGF-beta1. The suction blister fluid TGF-beta2 level remained below the sensitivity level of the immunoassay in many cases. Isotretinoin did not affect the serum TGF-beta1 or TGF-beta2 level. Betamethasone-17-valerate pretreatment for 3 days twice a day caused a statistically significant 17% decrease in suction blister fluid TGF-beta1. The active form of TGF-beta1 represented 5% of the total TGF-beta1 in suction blister fluid. Our diffusion calculations suggest that all TGF-beta1 and TGF-beta2 detected in suction blister fluid have diffused from systemic circulation. The increase in suction blister fluid TGF-beta1 after isotretinoin treatment seems to be of local origin, while the decrease in suction blister fluid TGF-beta1 after glucocorticoid pretreatment seems to be due to glucocorticoid-induced vasoconstriction resulting in decreased diffusion of TGF-beta1 from the circulation. Modulation of local interstitial fluid TGF-beta1 concentration may be one mechanism by which isotretinoin and glucocorticoids mediate their effects in skin.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Betamethasone 17-Valerate,
http://linkedlifedata.com/resource/pubmed/chemical/Isotretinoin,
http://linkedlifedata.com/resource/pubmed/chemical/Keratolytic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Lymphotoxin-alpha
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1422-2868
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2000 S. Karger AG, Basel
|
pubmed:issnType |
Print
|
pubmed:volume |
13
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
150-6
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10859533-Acne Vulgaris,
pubmed-meshheading:10859533-Adult,
pubmed-meshheading:10859533-Anti-Inflammatory Agents,
pubmed-meshheading:10859533-Betamethasone 17-Valerate,
pubmed-meshheading:10859533-Blister,
pubmed-meshheading:10859533-Body Fluids,
pubmed-meshheading:10859533-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:10859533-Humans,
pubmed-meshheading:10859533-Isotretinoin,
pubmed-meshheading:10859533-Keratolytic Agents,
pubmed-meshheading:10859533-Lymphotoxin-alpha,
pubmed-meshheading:10859533-Male
|
pubmed:articleTitle |
Differential modulation of transforming growth factor-beta by betamethasone-17- valerate and isotretinoin: corticosteroid decreases and isotretinoin increases the level of transforming growth factor-beta in suction blister fluid.
|
pubmed:affiliation |
Department of Dermatology, University of Oulu and Oulu University Hospital, Oulu, Finland.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|